Volume growth improves, but payor mix remains a drag
- DaVita makes most of its money from dialysis treatments paid for by Medicare, Medicaid, and commercial insurance.
- Treatment volume is expected to grow near the top of the 25 to 50 basis points range, helped by lower patient mortality.
- The company expects a $70 million drag in 2027 from a decline in commercial payor mix.
- DaVita is deploying expanded hemodialysis dialyzers broadly to improve long-term patient mortality by 2028.
- Share buybacks can lift EPS, but DaVita also carries a heavy debt load and must keep cash flowing.
The setup improved, but new headwinds emerged
DaVita continues to see better volume trends than initially feared. After Q2 2026, management raised volume growth expectations to the top end of the 25 to 50 basis points range. This was driven entirely by lower patient mortality, as the benefit from competitor clinic closures has fully played out. The company is also rolling out expanded hemodialysis dialyzers to improve long-term patient mortality starting in 2028.
The bull case is simple. Dialysis is a needed service, volume trends are stable, and the new dialyzers require minimal capital investment. If these gains hold and IKC adds covered lives, DaVita can offset cost inflation. Furthermore, ongoing share repurchases provide a continuous tailwind to EPS.
The bear case centers on the payor mix. Management expects the commercial mix headwind from expired ACA subsidies to result in a $40 million drag in 2026 and a $70 million drag in 2027. If broader employment shifts push more patients off commercial plans, revenue per treatment will fall. The stock needs DaVita to keep volumes, payor mix, costs, and buybacks all working at the same time.
Paid by the treatment
DaVita provides kidney dialysis, mostly in outpatient centers. A patient comes in for treatment, DaVita bills a payor, and the company earns revenue per treatment. The main payors are Medicare, Medicaid, Medicare Advantage, and commercial insurance.
The most important detail is the payor mix. Commercial insurance pays far more than government programs, so a small shift away from commercial patients can hurt profit. This is why ACA enrollment and commercial mix commentary matter so much.
DaVita is also building Integrated Kidney Care, or IKC. In IKC, DaVita tries to manage the full cost and quality of care for kidney patients, not just provide dialysis. The company also recently invested $200 million in Elara Caring to target home health services.
Kidney care pieces
U.S. in-center hemodialysis
This is the core business. It provides recurring dialysis treatments in DaVita clinics and drives most revenue and operating profit.
Related lab services
Lab services support dialysis care and sit inside the U.S. dialysis business. They add scale around the main treatment network.
Oral phosphate binders
These drugs are now part of the Medicare dialysis benefit. They create a new revenue stream, but also bring new drug cost and reimbursement risk.
Integrated Kidney Care
IKC is DaVita's value-based care business. It became profitable in 2025, one year ahead of plan, and continues to add covered lives.
International dialysis clinics
DaVita operates clinics outside the United States and continues to look at acquisitions.
Home health investments
A recent $200 million investment in Elara Caring aims to bring dialysis-tailored home health services to patients.
One core segment dominates
Mix uses Q1 2026 external revenues from DaVita's 10-Q revenue table: U.S. dialysis at $2.921 billion and other ancillary services at $494 million. Other ancillary bundles IKC, international, and smaller U.S. ancillary lines.
What could break the story
Commercial mix slips faster
High impact · High oddsDaVita earns much more from commercial insurance than from government programs. Management expects a $40 million hit in 2026 and a $70 million drag in 2027 as new admits lean away from commercial plans.
Volume gains face harder comparisons
Medium impact · Medium oddsThe benefit from competitor clinic closures is now complete. While volume expectations have improved to the high end of the 25 to 50 basis point range, it now relies entirely on lower patient mortality rather than market share gains.
Reimbursement trails cost inflation
High impact · Medium oddsDialysis is labor intensive, and DaVita has faced higher wage, medical supply, and IT costs. The 2027 ESRD final rule may not cover structural cost inflation. If cost per treatment rises faster than revenue, margins can compress.
Debt and buybacks limit flexibility
Medium impact · Medium oddsDaVita uses a lot of debt and buys back stock aggressively. Buybacks help EPS, but they also use cash that could otherwise reduce leverage or fund growth in home health and value-based care.
In one breath
What does DaVita do?
DaVita provides dialysis for people with kidney failure. Most care happens in outpatient centers, where patients receive recurring treatments and DaVita bills Medicare, Medicaid, Medicare Advantage, or commercial insurance.
Why does commercial insurance matter so much for DaVita?
Commercial plans pay much more than government programs for dialysis. That means a small move in commercial mix can have a large effect on revenue per treatment and profit.
What changed after Q2 2026?
Management reported solid volume growth driven by better patient mortality and announced a shift to expanded hemodialysis. However, they expect a $70 million profit hit in 2027 as fewer new patients have commercial insurance.
Is Integrated Kidney Care important?
Yes, but it is still smaller than core dialysis. IKC became profitable in 2025, one year ahead of plan, and is meant to manage total kidney care costs.
